Condition: Solid Tumors · Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
This description comes directly from the study's public registry record.
Serena Dong · 051269566088 · suhua.dong@innoventbio.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Arizona | Pheonix, Arizona, United States | Recruiting |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | Recruiting |
| Montefiore Cancer Center | New York, New York, United States | Recruiting |
| NEXT Houston | Houston, Texas, United States | Recruiting |
| NEXT Dallas | Irving, Texas, United States | Recruiting |
| The sixth affiliated hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06963281